Literature DB >> 21544013

Uni- and bilateral instrumented posterolateral fusion of the lumbar spine with local bone grafting: a prospective study with a 2-year follow-up.

Seiji Ohtori1, Takana Koshi, Munetaka Suzuki, Masashi Takaso, Masaomi Yamashita, Kazuyo Yamauchi, Gen Inoue, Sumihisa Orita, Yawara Eguchi, Nobuyasu Ochiai, Shunji Kishida, Kazuki Kuniyoshi, Yasuchika Aoki, Junichi Nakamura, Tetsuhiro Ishikawa, Gen Arai, Masayuki Miyagi, Hiroto Kamoda, Miyako Suzuki, Takeo Furuya, Tomoaki Toyone, Kazuhisa Takahashi.   

Abstract

STUDY
DESIGN: Prospective trial.
OBJECTIVE: To examine the bone union and clinical results after unilateral or bilateral instrumented posterolateral fusion surgery using a local bone graft. SUMMARY OF BACKGROUND DATA: The iliac crest bone graft technique for lumbar posterolateral fusion surgery is widely used; however, donor site problems such as pain and sensory disturbance have been reported. Local bone has been used for bilateral multisegment fusion surgery; however, outcomes have been poor because of insufficient amounts of local bone used. This study evaluated unilateral and bilateral posterolateral fusion at 3 levels using a local bone graft.
METHODS: Sixty-two patients diagnosed with degenerated spondylolisthesis at 3 levels were divided into 2 groups. All underwent decompression and bilateral instrumented posterolateral fusion. However, a unilateral local bone graft was used in 32 patients and bilateral local bone graft was used in 30 patients. The amount of bone grafting, proportion of patients with bone union, duration of bone union, visual analog scale score, Japanese Orthopedic Association score, and Oswestry Disability Index were evaluated before and 2 years after surgery.
RESULTS: Visual analog scale score, Japanese Orthopedic Association score, and Oswestry Disability Index were not significantly different between the 2 groups before and after surgery (P > 0.05). The amount of local bone graft used for each segment was significantly less in the bilateral group (P < 0.05). The proportion of patients with rates of bone union and instability were 86% and 9%, respectively, in the unilateral group, but significantly poorer at 60% and 34% in the bilateral group.
CONCLUSION: If multisegment fusion (3-level fusion) is performed, bilateral local bone grafting results in a poor rate of bone union because of an insufficiency of local bone. Unilateral bone grafting is recommended because better rates of bone union and stability are achieved.

Entities:  

Mesh:

Year:  2011        PMID: 21544013     DOI: 10.1097/BRS.0b013e31821f50de

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  Outcomes of direct lateral interbody fusion (DLIF) in an Australian cohort.

Authors:  Daniel B Scherman; Prashanth J Rao; Kevin Phan; Sean F Mungovan; Kenneth Faulder; Gordon Dandie
Journal:  J Spine Surg       Date:  2019-03

Review 2.  Improving the clinical evidence of bone graft substitute technology in lumbar spine surgery.

Authors:  Wellington K Hsu; M S Nickoli; J C Wang; J R Lieberman; H S An; S T Yoon; J A Youssef; D S Brodke; C M McCullough
Journal:  Global Spine J       Date:  2012-10-09

3.  Bone Union Rate Following Instrumented Posterolateral Lumbar Fusion: Comparison between Demineralized Bone Matrix versus Hydroxyapatite.

Authors:  Woo Dong Nam; Jemin Yi
Journal:  Asian Spine J       Date:  2016-12-08

4.  Multilevel instrumented posterolateral lumbar spine fusion with an allogeneic cellular bone graft.

Authors:  John F Hall; Julie B McLean; Savannah M Jones; Mark A Moore; Michelle D Nicholson; Kimberly A Dorsch
Journal:  J Orthop Surg Res       Date:  2019-11-15       Impact factor: 2.359

5.  Lumbar Spine Fusion Rates With Local Bone in Posterolateral and Combined Posterolateral and Interbody Approaches.

Authors:  Daniel K Park; Richard Roberts; Paul Arnold; David H Kim; Rick Sasso; Kevin C Baker; Jeffrey S Fischgrund
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2019-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.